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with known premature Cl io is important and may influence subsequent risk 
of early CHD in asymptomattc family members. 
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-9~ Ten Year Trends in Cam for Corzgestive Hospital 
Heart Failure: Improved Ou~-omes. Increased 
Procedures and Higher Costs 
C.A. Polanczyk. LE.P. Ro~de. M. Call. T. DiSah~. Massachusetts General 
Hos~mk Bos~,n. MA. USA 
Chaxcj~ o~er ttme in outcomes and resource ubl~.abon m hosptal care ol 
congestive heart failure (CHF) have not been widely sludmd. To examine 
tre~ls of mortality rates, resource utdizatJon and cosls in patients edmittsd to 
an academic medical center, all 6,676 pahents hospitalized with pnman/ICD-9 
drag~:~ses of CHF between 1986 apd 1996 were ~ .  Palfi~nt outcomes 
and resource utilizatton were ~sk-adlUSted for sooo..demog~ic harec- 
tenstics and assooated comod~ties using muffiple regression analyses. A 
yearly, discount rate of 7% was used to convert all costs to 1996 US$. 
Resu/ts (see teb4e): The mean age was 70 + 13 years, 54% were male 
and 8"/% were white. FOr all trends, p value <0.01. Invaswe prooedures = 
cardiac catheterization, PTCA. CABG, IABP, mechamcat ventilation, invas=ve 
hemedynamic monitoring and dialysis. 
Conclus~n: A signifcant decrease in hospital mortality was observed in 
a 10 year period, even after controlling for soc~o-demographic characteristics 
Years 1986--87 1988--89 1990-91 1092-93 1994~96 
(n=942) (n=1126) (n=1302) (n81411) (n=1896) 
ln.h ospital mot  aid'y. % 8.4 8.5 7.1 6.3 6.1 
Ad~sted motla|~tv 9.1 8.8 6.7 5.7 6,4 
Invasive Procedures. % 19 21 24 28 24 
Length of stay. days 9.8 10.7 11.2 10.3 8.8 
Adjusted length of ~ay 10.4 11.0 10.9 9.9 8.9 
Total costs. 1996 US$ 2.814 4.182 7.036 10.760 12.759 
Adjusted total costs 2.800 4.107 6.913 10.579 13.039 
and comort~o'ffle8, These clara indcat~ tt~! the ¢1e¢~ m mortatlly was 
achm'~:l at tho expense of increased proceclum ulihzaho~ and h~gher overall 
hesr~lal costs, 
~ ImlNmt of t tN I th  Imlu~ ~ on Outcome in 
I~kmm With Advon¢~114eort F i I lum Refwr~l  for 
Hur t  Tr lmlp l ln lM!on 
JA. Waldtm, M,A, Haf~lt0n, G,C. FoNifow, MA. Woo, N,A I.~in01!I0~, 
^. Hage, JO, Mortguchi. UCLA MecI~al Ce~. , Lo~Angek~ CA, t/SA 
To ~ me impect ~ I~l lh  msurm~ stature cm (:~mm outcome in acl. 
v~no~i heart fa*lum, w~ ~ 563 ~ who w~re ewJuate0 and ac- 
tep id  for heart tm~Uon (Tx) t~twetm 1~P2 and 1~u9~,/U~ 
were ~ at 6 ~n~m~ of e~mry 2-3 months m t~e heart lai!um oemer, t~t 
no~HMO pt= had g l~m 4¢ce~ tO ~ ¢llm. P ~  were 91 ~ 
ba,~ed on the~¢ Pf~W ~ in~n,n~o (~0emge ~nd ana~ for 
se~ al bn~ of referral, peecenl t~ l l ted ,  sl~tt~s elf time of Tx, ~md sur- 
vival. In em four m~mnce ¢~legoncs, 168 (34%) pt~ ha0 p~vale insurance 
(P), 123 (22%) heel managed ¢~m p~na (HMO), 148 (26%) ha~ Me¢ltcam 
(MCR), and t 04 (18%) had MedcaKI (MCD). ~ 4 gmupe had =lr~lar 
of illness ~ at ~ 0! mfewal (mean @ 52 y~. NYHA 3.5, LVEF 24). 
W~th average f/u of 19 mont~, no differences were ~m~ m fotal modal~. 
Howevm. a g~er  pmpe~ of HMO pte mqu~md u~0e~ 1'I (20%), corn- 
pined Io P, MCR, and MCD (15%, 1~,  19% p < 0.0C01, p = 0.02, p = 0.18) 
~d~on~dly, fe~,~r HMO I~ were able to avord Tx (44%), compam~ fo P and 
MCD (5~%, 61% p = 0.04, p = 0.02). 
Cm~m~- Anlx~gh ove~a~ mmmml was em~ar aoo~ all mmmmce 
groups, pa'dents ~,ec l  uncl~ ~ cam p~s requ,ed urgem I~m 
van,~plammion morn f~lU~-d~y and we,e le~ ~ely to ave~l Iran~l~mm~on 
~ access to a heart fm]um spacmMy center may help to ~ 
c~,.ca~ mb~y an~ anow pa~e~s to dete~ Wansp~anta~o~ v hout adveme~/ 
e ~  surwval. 
~ ldemli~in 9 Patients Risk for Recurrent at Hospnal 
Admission for Heart Failure 
EF ~ J.B. I:kerde~. Het~/FottYHo~i~a/. C~hu~L Aft& 
Hea~lca~e. Coc~,stown. N~, USA 
Back~R:~Jncf: ReoJrrent hes~ admm~on~ for HF are &arrmngly common; 
the pred~cto~ of ma~.=.on am not well Imown. 
Me,J~oo~: ~ me New yo~ sta~e,.~ ; -~ ia l  data set we compared Ihe 
foflowmo ~ 9.112 patm~ts ~ only 1 HF acb~s~io~ and 33,619 w~h 
>1 d~ 1095: Oemographf¢~.  illness. ~ta l  lyt'l~O(~l~ L~ 
processes of care. A simple readn~ss~on Risk Score was denved by count- 
iP.g Itte nomi0~r of pO~lhVe ~Om pre~ant ~ ~ =lumber o1' rNi~al~ve 
predmtora 
Result- Rez~l~ls$,on was independ~ntty related to black race, Medicaid 
a~d MedCam msuranoe, ~;~,,~.,1 ~=p~al, ~eme~ monit~ng, disc~r~ 
against a<Ntce, and these comorbKM~s: i~:~remic end ~,alvular head cl~- 
ease. ~,,~.athic arcbo~/opall~/, d~ie-~, renal disease, COPD, pdor heart 
surgmy, b e ~  vascular disease and anemsa. Dmchefge to a numtng 
home. cardmc cath and ~ were related to lower risk. Shawn 
rs the incremental relabonsh~p between Rink Score and readmts~o~ rate: 
Score Rate Sco~ P~le S¢om Ram 
3 to 0 0 6% 3 20.0'% 6 29.7%, 
t 13.6% 4 23.1~0 7 34~,~ 
2 166% 5 263"='= ,8 400% 
ConcYus~o~s: 1) Using a large, co.-nl~rehensNe data set not restrcted by 
insurance payor, we identified ~gnificam i~'eo~¢to rs of recurrent 8o~l'fisston for 
HF: 2) our simple Risk Score m~ght De used to )dentlty candidates for care 
management to reduce readmissions 
~ W a a t  Matters to Patients With Severe Heart Really 
Failure: Tradeoffs Between Quantity and Quality 
of Life 
K.D. Aaronson. J HoaShi, J. Bowers. T.-M. Chen. UnwerstlyofM~htgan 
Medical Center, Ann Arbor. ML USA 
Backgn:~-~: Although development and approval of drugs for CHF is largely 
focused on improving sunlival, a drug's impact on quantity of life may differ 
from its effect on quality of life (QOL). How patients (pts) with severe CHF 
value quantity vs. QOL is unknown. 
Methods: We assessed the willingness of outpatients with chronic NYHA 
class Ill (n = 44) or IV (n = 3) CHF to accept decreased (~uant~ty to obtain im- 
proved QOL QOL was assessed with the Living with Heart Failure Question- 
naire (LHFQ). Utility for CHF-related QOL w~s assessed ~' st=_ndard gamble 
